agilon health, inc.

As of June 30, 2026, agilon health, inc. carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 1.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

agilon health, inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, agilon health, inc. has 16.79M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.30, and the price-to-book ratio stands at 7.91.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.65B versus a market cap of 1.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, agilon health, inc. maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.70, indicating elevated leverage, while an interest coverage ratio of -40.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, agilon health, inc. posted a negative return on equity (ROE) of -72.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.06, reflecting losses generated across the asset base. The company generates approximately 6.50M in revenue per employee across its workforce of 911.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, agilon health, inc. recorded 646,000.00 in income tax expense. The company reported a pretax loss of -250.57M and -232.22M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, agilon health, inc.'s stock has gained approximately 283.44% over the past 52 weeks. The 50-day moving average sits at 88.51, while the 200-day moving average is 63.02.

Over the twelve months ended June 30, 2026, agilon health, inc. generated 5.92B in revenue and converted that into -232.22M in net income, yielding earnings per share of -14.99. EBITDA reached -281.28M, while operating income came in at -273.25M.

As of June 30, 2026, agilon health, inc. holds 185.63M in cash and equivalents against 33.45M in total debt, resulting in a net debt position of -76.89M. Total book value stands at 227.53M, with working capital of 106.19M providing operational flexibility.

agilon health, inc. produced -72.26M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -33.72M in capital expenditures, free cash flow totaled -105.98M - equivalent to -6.38 per share.

Over the twelve months ended June 30, 2026, agilon health, inc. posted a gross margin of 0.23, reflecting its pricing power and cost economics. The operating margin of -4.62 and net profit margin of -3.92 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to agilon health, inc. shareholders.

agilon health, inc.'s most recent stock split took place on March 31, 2026 with a 25:1 split ratio.

As of June 30, 2026, agilon health, inc. has an Altman Z-Score of 2.40, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.